Today, CellaVision announces that the company's Annual and Sustainability Report for 2025 is available as PDF at www.cellavision.com and can be read via the link below.
In accordance with the company's environmental policy, the company has decided to print the 2025 Annual and Sustainability Report only in a small number of copies. To request a printed version, please visit the investor pages at the CellaVision website.
Contact
Helena Raihle
Corporate Communications & Investor Relations
Tel: + 46 70 822 70 93
www.cellavision.com
helena.raihle@cellavision.com
About Us
CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 13 local market support organizations covering more than 40 countries. In 2025, sales were SEK 759 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com
This information is information that CellaVision is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-01 08:20 CEST.